At a glance
- Originator Bristol-Myers Squibb
- Class Antiglaucomas
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 15 Mar 2001 No-Development-Reported for Glaucoma in USA (Ophthalmic)
- 23 Jul 1997 New profile
- 23 Jul 1997 Preclinical development for Glaucoma in USA (Ophthalmic)